MedTrace Logo

Immunosuppression Optimization Using The Prospera Assay In Kidney Transplant Recipients (IMPAKT)

NCT07718633 · Status: NOT_YET_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 750

Last updated 2026-07-22

No results posted yet for this study

Summary

IMPAKT is a research study that looks at whether a blood test called Prospera™ can help doctors better adjust anti-rejection medications, compared to the usual way doctors manage these medications without using this test.

Conditions

  • Kidney Transplant
  • Immunosuppresion

Interventions

DIAGNOSTIC_TEST

Prospera Immunosuppression Optimization

The test arm will include participants who are managed with routine clinical care, along with a standardized dd-cfDNA protocol, to guide optimization of immunosuppression dosages.

Sponsors & Collaborators

  • Natera, Inc.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-07-31
Primary Completion
2027-12-31
Completion
2031-07-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07718633 on ClinicalTrials.gov